🇺🇸 FDA
Patent

US 7842704

Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

granted A61KA61K31/439A61K31/445

Quick answer

US patent 7842704 (Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity) held by Theravance, Inc. expires Mon Nov 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Nov 30 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/439, A61K31/445, A61K31/4545, A61P